Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive cancers, with a 5-year survival rate below 10%. This poor prognosis is mainly due to late diagnosis, high resistance to chemotherapy, and the rapid deterioration of patients’ health, often marked by severe cachexia that limits access to surgery or treatment.
The FRAP project (French Research Network against Pancreatic Adenocarcinoma) is one of the two laureates of the 2024 Call for Applications launched by the French National Cancer Institute. Its objective is to promote and support research networks of excellence focused on cancers with poor prognoses.
Coordinated by Professor Jérôme Cros (Beaujon Hospital, Clichy), FRAP brings together 15 research teams and associated partners, including oncology cooperative groups, clinical experts, and patient organizations. Together, they aim to accelerate progress in understanding and treating pancreatic cancer.
Building a national resource hub dedicated to pancreatic cancer, including a pre-clinical hub, a tissue hub, and a molecular data and analysis hub.
Advancing translational and basic research, studying the impact of the exposome on PDAC, tumor–microenvironment interactions, and the systemic effects of the disease on metabolism and quality of life. This includes supporting innovative proof-of-concept projects responding to the 2025 FRAP call for research.
Bridging research and clinical care by validating predictive biomarkers, developing innovative therapies, and improving clinical trials through patient-centered, multidisciplinary evaluation criteria.
